-
公开(公告)号：WO2020178742A1
公开(公告)日：2020-09-10
申请号：PCT/IB2020/051811
申请日：2020-03-03
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： HIRANO, Naoto , MURATA, Kenji , SASO, Kayoko
IPC: C12N15/62 , A61K31/675 , A61K31/7076 , A61K35/12 , A61K35/17 , A61K38/20 , A61P35/00 , C07F9/6584 , C07K14/705 , C07K14/725 , C07K14/74 , C07K19/00 , C12N15/113 , C12N15/12 , C12N15/55 , C12N15/867 , C12N5/078 , C12N5/0783 , C12N5/10 , C12N5/12 , G01N33/566
Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.
-
公开(公告)号：WO2020178740A1
公开(公告)日：2020-09-10
申请号：PCT/IB2020/051809
申请日：2020-03-03
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： HIRANO, Naoto , MURATA, Kenji , SASO, Kayoko
IPC: C12N15/62 , A61K31/675 , A61K31/7076 , A61K35/12 , A61K35/17 , A61K38/20 , A61P35/00 , C07F9/6584 , C07K14/705 , C07K14/725 , C07K14/74 , C07K19/00 , C12N15/113 , C12N15/12 , C12N15/55 , C12N15/867 , C12N5/0783 , C12N5/10 , G01N33/566
Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.
-
公开(公告)号：WO2020172485A1
公开(公告)日：2020-08-27
申请号：PCT/US2020/019142
申请日：2020-02-21
Inventor： ANDREEFF, Michael , ISHIZAWA, Jo , SCHIMMER, David , ZARABI, Sara
IPC: A61K31/519 , A61K31/505 , A61P35/00 , A01N43/54
Abstract: Provided herein are methods of using ClpP levels and mutation status as a marker for the selection and treatment of cancer patients who will respond to the administration of imipridones. Also provided are methods of treating patients having Perrault syndrome. Also provided are methods of killing bacterial cells and treating bacterial infections using imipridones.
-
104.发明申请
公开(公告)号：WO2020034043A1
公开(公告)日：2020-02-20
申请号：PCT/CA2019/051121
申请日：2019-08-16
Inventor： CYPEL, Marcelo , WANG, Aizhou , KESHAVJEE, Shafique , WITHERS, Stephen G. , RAHFELD, Peter , KIZHAKKEDATHU, Jayachandran
Abstract: Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods, uses, associated therewith. In particular, the perfusion fluids comprise two enzymes, GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore, the compositions described herein were found to have activity at temperatures and pH levels suitable for cell viability.
-
公开(公告)号：WO2020028324A1
公开(公告)日：2020-02-06
申请号：PCT/US2019/044075
申请日：2019-07-30
Applicant: THE JOHNS HOPKINS UNIVERSITY , UNIVERSITY HEALTH NETWORK
Inventor： POMPER, Martin G. , MEASE, Ronnie C. , CHEN, Ying , RAY, Sangeeta , CHEN, Juan , OVERCHUCK, Marta , HARMATYS, Kara , ZHENG, Gang
Abstract: Theranostic probes comprising a porphyrin-based photosensitizer, a D-peptide linker, and a urea-based PSMA-targeting ligand and methods of their use for treating and/or imaging PMSA-expressing tumors are disclosed.
-
Patent Agency Ranking106.发明申请
公开(公告)号：WO2019210218A1
公开(公告)日：2019-10-31
申请号：PCT/US2019/029421
申请日：2019-04-26
Inventor： PAULSEN, Keith D. , ROBERTS, David W. , WIRTH, Dennis , WILSON, Brian C. , SIBAI, Mira
Abstract: A method and device for determining the depth and fluorophore concentration of a fluorophore concentration below the surface of an optically absorbing and scattering medium suitable for use in fluorescence-based surgical guidance such as in tumor resection is described. Long-wavelength stimulus light us used to obtain deep tissue penetration. Recovery of depth is performed by fitting measured modulation amplitudes for each spatial frequency to precomputed modulation amplitudes in a table of modulation amplitudes indexed by optical parameters and depth.
-
公开(公告)号：WO2018184100A1
公开(公告)日：2018-10-11
申请号：PCT/CA2018/050400
申请日：2018-03-29
Applicant: UNIVERSITY HEALTH NETWORK , BAGNATO, Vanderlei, Salvador
Inventor： BAGNATO, Vanderlei, Salvador , CYPEL, Marcelo , KESHAVJEE, Shafique , WADDELL, Thomas, Kenneth , GALASSO, Marcos, Theophilo
Abstract: Disclosed are apparatuses and methods for irradiating a perfusate. The apparatus includes a tank which defines a first chamber. A separator is located inside the first chamber. The separator defines a second chamber. The first chamber and the second chamber are concentric and have substantially annular cross sections, each having at least one diameter and a substantially common longitudinal axis. A perfusate is introduced into the first chamber by an inlet. A UV radiation-emitting device is disposed inside the second chamber for providing irradiation to the perfusate. Irradiated perfusate is removed from the tank by an outlet. Other apparatuses and systems are described and methods for inactivating micro organisms by performing EVP and irradiating the perfusate.
-
公开(公告)号：WO2018058258A1
公开(公告)日：2018-04-05
申请号：PCT/CA2017/051171
申请日：2017-10-02
Applicant: UNIVERSITY HEALTH NETWORK , CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
Inventor： MCCART, Judith, Andrea , STOJDL, David, Francis , HO, Tiffany, Yun-Yee
IPC: C12N15/863 , A61K35/768 , A61P35/00 , C07H21/04 , C12N15/39 , C12N15/85 , C12N15/86 , C12N5/10 , C12N7/01
Abstract: The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the use of these recombinant oncolytic poxvirus in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating recombinant oncolytic poxviruses including for example vaccinia viruses that have one or more inactivated immunomodulatory genes.
Abstract translation: 本公开提供了包含痘苗病毒的重组溶瘤痘病毒，所述痘苗病毒包含选自NIL，K1L，K3L，A46R和/或A52R的一种或多种失活的免疫调节基因，任选地还包含失活的TK和/或VGF基因 。 本公开内容还提供了在溶瘤病毒疗法中这些重组溶瘤痘病毒的使用方法和方法。 本发明还提供了用于产生重组溶瘤痘病毒的载体构建体，包括例如具有一个或多个失活的免疫调节基因的痘苗病毒。
-
公开(公告)号：WO2018007924A3
公开(公告)日：2018-01-11
申请号：PCT/IB2017/053991
申请日：2017-06-30
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： NIJJAR, Tarlochan S. , CHAKRABARTTY, Avijit , HIGAKI, Jeffrey N
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：WO2018007924A2
公开(公告)日：2018-01-11
申请号：PCT/IB2017/053991
申请日：2017-06-30
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： NIJJAR, Tarlochan S. , CHAKRABARTTY, Avijit , HIGAKI, Jeffrey N
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
-
-
-
-
-
-
-
-
Search Results
1331
records
(took 0.039 seconds)
